TY - JOUR
T1 - Amelioration of Neurochemical Alteration and Memory and Depressive Behavior in Sepsis by Allopurinol, a Tryptophan 2,3-Dioxygenase Inhibitor
AU - Metzker, Kiuanne Lino Lobo
AU - Mathias, Khiany
AU - Machado, Richard Simon
AU - Bonfante, Sandra
AU - Joaquim, Larissa
AU - da Silva, Marina Goulart
AU - Daros, Guilherme Cabreira
AU - Lins, Elisa Mitkus Flores
AU - Belle, Fernanda
AU - Alano, Carolina Giassi
AU - Matiola, Rafaela Tezza
AU - da Silva Lemos, Isabela
AU - Danielski, Lucinéia Gainski
AU - Gava, Fernanda Frederico
AU - de Bitencourt, Rafael Mariano
AU - Bobinski, Franciane
AU - Streck, Emilio Luiz
AU - Reus, Gislaine Zilli
AU - Petronilho, Fabricia
N1 - Publisher Copyright:
© 2024 Bentham Science Publishers.
PY - 2024
Y1 - 2024
N2 - Background: In response to inflammation and other stressors, tryptophan is catalyzed by Tryptophan 2,3-Dioxygenase (TDO), which leads to activation of the kynurenine pathway. Sepsis is a serious condition in which the body responds improperly to an infection, and the brain is the inflammation target in this condition. Objective: This study aimed to determine if the induction of TDO contributes to the permeability of the Blood-Brain Barrier (BBB), mortality, neuroinflammation, oxidative stress, and mitochondrial dysfunction, besides long-term behavioral alterations in a preclinical model of sepsis. Methods: Male Wistar rats with two months of age were submitted to the sepsis model using Cecal Ligation and Perforation (CLP). The rats received allopurinol (Allo, 20 mg/kg, gavage), a TDO inhibitor, or a vehicle once a day for seven days. Results: Sepsis induction increased BBB permeability, IL-6 level, neutrophil infiltrate, nitric oxide formation, and oxidative stress, resulting in energy impairment in 24h after CLP and Allo administration restored these parameters. Regarding memory, Allo restored short-term memory impairment and decreased depressive behavior. However, no change in survival rate was verified. Conclusion: In summary, TDO inhibition effectively prevented depressive behavior and memory impairment 10 days after CLP by reducing acute BBB permeability, neuroinflammation, oxidative stress, and mitochondrial alteration.
AB - Background: In response to inflammation and other stressors, tryptophan is catalyzed by Tryptophan 2,3-Dioxygenase (TDO), which leads to activation of the kynurenine pathway. Sepsis is a serious condition in which the body responds improperly to an infection, and the brain is the inflammation target in this condition. Objective: This study aimed to determine if the induction of TDO contributes to the permeability of the Blood-Brain Barrier (BBB), mortality, neuroinflammation, oxidative stress, and mitochondrial dysfunction, besides long-term behavioral alterations in a preclinical model of sepsis. Methods: Male Wistar rats with two months of age were submitted to the sepsis model using Cecal Ligation and Perforation (CLP). The rats received allopurinol (Allo, 20 mg/kg, gavage), a TDO inhibitor, or a vehicle once a day for seven days. Results: Sepsis induction increased BBB permeability, IL-6 level, neutrophil infiltrate, nitric oxide formation, and oxidative stress, resulting in energy impairment in 24h after CLP and Allo administration restored these parameters. Regarding memory, Allo restored short-term memory impairment and decreased depressive behavior. However, no change in survival rate was verified. Conclusion: In summary, TDO inhibition effectively prevented depressive behavior and memory impairment 10 days after CLP by reducing acute BBB permeability, neuroinflammation, oxidative stress, and mitochondrial alteration.
KW - 3-dioxygenase
KW - blood-brain barrier permeability
KW - catalase
KW - cognitive impairment
KW - oxidative stress
KW - Sepsis
KW - tryptophan-2
UR - http://www.scopus.com/inward/record.url?scp=85205106051&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85205106051&partnerID=8YFLogxK
U2 - 10.2174/0118715273282363240415045927
DO - 10.2174/0118715273282363240415045927
M3 - Article
C2 - 38712373
AN - SCOPUS:85205106051
SN - 1871-5273
VL - 23
SP - 1499
EP - 1515
JO - CNS and Neurological Disorders - Drug Targets
JF - CNS and Neurological Disorders - Drug Targets
IS - 12
ER -